Pharmaceutical

Anti-RANKL Monoclonal Antibody by Jiangsu Pacific Meinuoke Bio-Pharmarceutical for Osteoporosis: Likelihood of Approval

Anti-RANKL Monoclonal Antibody is under clinical development by Jiangsu Pacific Meinuoke Bio-Pharmarceutical and currently in Phase I for Osteoporosis.

Jun 20, 2024 - 04:00
Anti-RANKL Monoclonal Antibody by Jiangsu Pacific Meinuoke Bio-Pharmarceutical for Osteoporosis: Likelihood of Approval
Anti-RANKL Monoclonal Antibody is under clinical development by Jiangsu Pacific Meinuoke Bio-Pharmarceutical and currently in Phase I for Osteoporosis.
Read the original article

Tags:

Previous Article

ILution travoprost by Glaukos for Ocular Hypertension: Likelihood of Approval

Next Article

IBI-343 by Innovent Biologics for Solid Tumor: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

DEA organises Drug Take Back Day to fight addiction

DEA organises Drug Take Back Day to fight addiction

Apr 22, 2023

STAT+: Northeastern among sites chosen by CDC to establish ‘National Weather Service’ for infectious disease

STAT+: Northeastern among sites chosen by CDC to establ...

Sep 20, 2023

STAT+: UnitedHealth says medical costs aren’t soaring. The reality is murkier

STAT+: UnitedHealth says medical costs aren’t soaring. ...

Apr 15, 2023